HiringSelective
59/100
1 relevant signal
E
AI biotechnology · United States
Enveda
Current work outlook
Enveda closed a $311 million Series E financing led by Catalio Capital Management. The company said proceeds will advance three clinical-stage medicines into later development, bring additional inflammatory and metabolic programs into clinical trials and scale its AI-native drug-discovery platform.
Updated September 23, 2026 · Evidence from public sources
Flags outlook69/ 100Positive
1 verified signal in this assessment
Why this score
Built from company events, not anonymous ratings.
The recent evidence is constructive, but the specific role and team still matter. The score weighs signal recency and source confidence. It is a decision aid—not a verdict on culture or a specific team.
StabilityMixed
60/100
1 relevant signal
Financial healthStronger
66/100
1 relevant signal
InnovationNot enough data
We need a relevant verified event before scoring this dimension.
What moved the outlook
Company timeline
What changed—and why it matters
Read events in order and look for repeated momentum or recurring risk.
Filter in all signals ↗Enveda raises $311 million to advance AI-discovered medicines and scale its platform
Enveda closed a $311 million Series E financing led by Catalio Capital Management. The company said proceeds will advance three clinical-stage medicines into later development, bring additional inflammatory and metabolic programs into clinical trials and scale its AI-native drug-discovery platform.
Employee impact
Read full analysis →The funding supports both clinical execution and platform scale, which may strengthen demand across machine learning, data engineering, computational biology, chemistry and clinical operations. Biotech programs remain milestone-driven and capital intensive, so candidates should identify whether a role is attached to a funded clinical program or the broader research platform.